Hanna I Hyry,Timothy M Cox,Jonathan C P Roos
Hanna I Hyry
Orphan-drug sales are rocketing, with revenue expected to total $176 billion annually by 2020. As a share of the industry, orphan drugs now account for close to 15% of all prescription revenue globally (excluding generics) and the sector is...
Michael D Seckeler,Ian D Thomas,Jennifer Andrews et al.
Michael D Seckeler et al.
Adults living with congenital heart disease (CHD) now outnumber children with the disease. Thanks to medical advances over the past 75 years, many of these fatal childhood heart problems have changed to chronic medical conditions. As the po...
Valuing inter-sectoral costs and benefits of interventions in the healthcare sector: methods for obtaining unit prices [0.03%]
卫生部门干预措施的行业间成本效益：获取单价的方法
Ruben M W A Drost,Aggie T G Paulus,Dirk Ruwaard et al.
Ruben M W A Drost et al.
Introduction: There is a lack of knowledge about methods for valuing health intervention-related costs and monetary benefits in the education and criminal justice sectors, also known as 'inter-sectoral costs and benefits'...
Older anti-TNF-α agents: why not group them for common indications in the EU? [0.03%]
老款抗TNF-α药物：欧盟为何不按相同适应症进行分类？
Livio Garattini,Francesca Ghislandi,Anna Padula
Livio Garattini
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis [0.03%]
大麻萃取口腔黏膜喷雾剂治疗多发性硬化症引发的僵直症状之成本效益模式研究
Adrien Gras,Julie Broughton
Adrien Gras
Background: Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required. This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for tre...
Cost-effectiveness of adherence-enhancing interventions: a systematic review [0.03%]
提高依从性的干预措施的成本效益：系统评价研究
Tzahit Simon-Tuval,Peter J Neumann,Dan Greenberg
Tzahit Simon-Tuval
Low patient adherence to health-related interventions is a major barrier to achieving healthcare goals and is associated with very high avoidable costs. Although several studies suggest that adherence-enhancing interventions can improve hea...
Volume-outcome relationship for peripheral endovascular interventions: a review of existing literature [0.03%]
外周血管介入治疗的量效关系现有文献综述
Sidakpal S Panaich,Nilay Patel,Kanishk Agnihotri et al.
Sidakpal S Panaich et al.
The incidence and prevalence of peripheral vascular disease has been increasing. When coexistent with coronary artery disease (CAD), it has shown to predict higher mortality along with poorer quality-of-life consequently leading to a marked...
A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America [0.03%]
帕金森病单药治疗的系统评价和混合治疗比较：对拉丁美洲的意义
Maribel Márquez-Cruz,Juan Pablo Díaz-Martínez,Herman Soto-Molina et al.
Maribel Márquez-Cruz et al.
Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyz...
Nursing diagnoses and interventions in the care of elderly patients undergoing surgery [0.03%]
老年手术患者的护理诊断及干预措施
Zahide Tuncbilek,Sevilay Senol Celik
Zahide Tuncbilek
Aim: The aim of this study was to determine nursing diagnoses and interventions in the care plans of elderly patients undergoing surgery. Methods: ...
Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme [0.03%]
澳大利亚药品福利计划中他汀类药物支出的成本驱动因素分析
L P Thai,J R Moss,B Godman et al.
L P Thai et al.
Introduction: The Australian Pharmaceutical Benefits Scheme (PBS) provides universal access to subsidized medicines. In 2013, statins as a class had the highest expenditure on the PBS. ...